AdOM is a development and commercial stage ophthalmic medical device company which uses hyperspectral technology to measure the dynamics of the tear film inner structures.
The TFI is a non-invasive imaging device which is designed to simultaneously measure the muco-aqueous and lipid sublayers of the eye, at a resolution dept of a few nanometers.
The TFI has now been registered with the U.S. Food and Drug Administration (under its Class I exemption for this device type)
Company’s Keywords:
<12
<
<2008
Your request has been submitted successfully.
Own or work here?